At Flatiron, we are unlocking HEOR evidence and insights to demonstrate the value of oncology treatments to stakeholders including payers, regulators, and providers. By leveraging our industry leading multinational oncology data assets from the US, UK, Germany, and Japan and unparalleled expertise, we’re generating a spectrum of tailored solutions configured for the specific evidence needs of life sciences companies.

The research showcases innovative approaches to real-world evidence—from transportability studies and cross-border data harmonization to bias assessments in AI-extracted data—that address the most challenging questions in the field and advance the science of what real-world evidence can achieve.

Join our experts at booth #515 to discover how Flatiron is transforming the possibilities of oncology research, development, and access.

This workshop offers an interactive, deep dive into transportability analyses, a crucial method for addressing the deprioritization of real-world evidence (RWE) and the harmonization challenges under the new EU HTA Regulation's Joint Clinical Assessment (JCA). Through a framework presentation, a hypothetical JCA case study, and discussion of novel methodologies like estimands, attendees will learn how to leverage international RWE to bolster evidence submissions and validate comparative effectiveness in this evolving regulatory landscape.

This session address the complex challenge of accurately characterizing lines of therapy (LOT) using real-world data (RWD), a necessity for robust HEOR research evaluating oncology outcomes and costs. Despite its clinical significance, RWD sources often lack the complete information required, and there is no standardized approach for defining LOT across health systems. Attend this session to engage with RWD and oncology experts to review international frameworks and collectively develop best practices for distinguishing LOT, and discuss best practices for distinguishing these lines in RWD.

This session is critical for stakeholders facing market access challenges for highly uncertain precision medicine technologies. The panel will introduce an operational LC-HTA framework and use an entrectinib case study to demonstrate advanced RWE generation, including target trial emulation and data fusion, for establishing comparative effectiveness and evolving value-for-money. This provides actionable strategies for planning global evidence and ensuring RWE transportability across international regulatory and reimbursement systems.

real-world-data-adverse-event-surviellence

Behind the Research: An Exploration of Real-World Data's Ability to Support Adverse Event Surveillance at ISPOR Europe

— Featured content

Go behind the research with Lockwood Taylor, PhD and Elsie Horne to learn more about real-world data’s ability to support safety surveillance and fulfill local-data needs in regulatory submissions. Their findings—being presented at ISPOR Europe—showcase Flatiron's commitment to methodological innovation and rigorous science in adverse event monitoring.

Flatiron Health at ISPOR Europe 2025

We know oncology data. We deliver oncology evidence.

Flatiron networking reception

Monday, November 10, 2025

19:30-22:30 GMT

Join us for an evening of networking, cocktails, and hors d’oeuvres. This is a great opportunity to connect with colleagues, industry peers, and the Flatiron team.

Speaking sessions

Is Transferring Evidence Across Europe a Herculean Task? The Opportunities and Challenges of Transportability Analyses in the Context of European Union Joint Clinical Assessments

presenter

Lines of Therapy in Oncology Real-World Data: Navigating Complexity for Robust Evidence

presenter

Operationalizing Life-Cycle Health Technology Assessment for Precision Medicine

presenter

Global evidence solutions

Real-World Data

Real-World Evidence Services

Flatiron FORUM

Meet our experts at booth #515

Our research

Descriptive Comparison of Patient Characteristics and Treatment Patterns in Metastatic NSCLC: US and France Cohorts to Inform Transportability

See this research

Connect with a flatiron expert

Are Real-World Survival Outcomes in Metastatic Breast Cancer Transportable Between the US and Austria?

See this research

Connect with a flatiron expert

Advancing Real-World Evidence in Diffuse Large B-Cell Lymphoma: Insights from EHR-Derived Data in the UK

See this research

Connect with a flatiron expert

Comparing Countries' Time to Treatment Initiation: A Study of Metastatic Breast Cancer in Austria and the United States

See this research

Connect with a flatiron expert

Assessing Bias in LLM-Extracted Real-World Data: A Health Equity Analysis of Access to Care and Outcomes in Metastatic Breast Cancer

See this research

Connect with a flatiron expert

Fit-for-Purpose Real-World Data: Lessons from FDA QCARD and EMA Data Quality Framework

See this research

Connect with a flatiron expert

Laboratory Testing Patterns in Patients with Breast Cancer Treated With CDK4/6 Inhibitors: A Multi-Country Electronic Health Record Study From the UK, Germany, and Japan

See this research

Connect with a flatiron expert

Incidence of Neutropenia Adverse Events Identified in Electronic Health Care Records Among Initiators of CDK4/6 Inhibitors With Advanced Breast Cancer in the UK

See this research

Connect with a flatiron expert

Transportability of Overall Survival in Multiple Myeloma From the US to Germany: A Benchmarking Study

See this research

Connect with a flatiron expert

Real-World Insights into Prostate Cancer Management Using EHR-Derived Data from the UK

See this research

Connect with a flatiron expert

Real-World Insights Into Breast Cancer in the UK: Findings From UK EHR-Derived Data

See this research

Connect with a flatiron expert

Real-World Study of Breast Cancer Epidemiology and Treatment Patterns: A Pilot Study to Assess EHR-Derived Data in the United Kingdom

See this research

Connect with a flatiron expert

Looking for support in designing and executing HEOR studies with RWE?

Request a meeting